Nath et al. suggested that alternative oncogenic pathways may compensate for the loss of BCR-ABL stimulation in TKI-treated patients [18]. Ultimately, this argues for a thorough analysis of the tumor prior to selecting therapy as do studies now involving analysis of BCR-ABL resistance mutations [13,15,17]. Here, ABL1 is linked to neoplasm.